HC Wainwright Reaffirms Buy Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB - Free Report) in a research note released on Friday, Benzinga reports. They currently have a $50.00 price target on the stock.

GMAB has been the subject of several other reports. Royal Bank of Canada raised shares of Genmab A/S from a sector perform rating to an outperform rating in a research note on Monday, July 15th. BTIG Research lifted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a buy rating for the company in a research note on Monday. Finally, Morgan Stanley reissued an equal weight rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of Hold and an average target price of $45.20.

Genmab A/S Trading Up 1.5 %

GMAB traded up $0.41 during trading hours on Friday, hitting $26.90. The company's stock had a trading volume of 502,471 shares, compared to its average volume of 572,483. The business's 50-day moving average price is $27.22 and its 200-day moving average price is $28.09. Genmab A/S has a 12 month low of $24.53 and a 12 month high of $38.80. The stock has a market cap of $17.79 billion, a price-to-earnings ratio of 22.08, a P/E/G ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The business had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, analysts forecast that Genmab A/S will post 1.27 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC purchased a new stake in Genmab A/S in the second quarter worth about $1,354,000. Point72 Asset Management L.P. bought a new position in Genmab A/S in the second quarter worth about $457,000. Cubist Systematic Strategies LLC raised its holdings in Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock worth $182,000 after purchasing an additional 478 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after purchasing an additional 103,859 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.